1. Randomised, double-blind, placebo-controlled study of pivagabine in neurasthenia.
- Author
-
Pizzolato G, Cagnin A, Mancia D, Caffarra P, Avanzi S, Copelli S, Ciappina C, Lo Presti F, Spilimbergo PG, D'Antonio E, Di Costanzo E, Matrango M, Pastres P, Urbani PP, Signorino M, Simoncelli M, Provinciali L, Regnicolo L, Albano C, Roccatagliata G, Rubino V, Cultrera S, and Fracassi M
- Subjects
- Adolescent, Adult, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Neurasthenia psychology, Psychiatric Status Rating Scales, Psychotropic Drugs adverse effects, gamma-Aminobutyric Acid adverse effects, gamma-Aminobutyric Acid therapeutic use, Neurasthenia drug therapy, Psychotropic Drugs therapeutic use, gamma-Aminobutyric Acid analogs & derivatives
- Abstract
One hundred and eighteen patients with neurasthenia, as defined by ICD 10 (International Classification of Diseases), participated in a randomised, double-blind, placebo-controlled trial of pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg). Pivagabine 1800 mg/d was administered orally for four weeks. At the end of the trial, active medication was significantly superior to placebo on the Clinical Global Impression (CGI) improvement of illness scale. In addition, pivagabine treatment reduced the physical and mental fatigability of patients, and increased their sense of well-being.
- Published
- 1997